Cti Biopharma 's Revenue in the fiscal year 2022 $ 53.95 millions
Cti Biopharma 's Revenue in the fiscal year 2021 $ 0.00 millions
Cti Biopharma 's Revenue in the fiscal year 2020 $ 0.00 millions
Cti Biopharma 's Revenue in the fiscal year 2019 $ 3.35 millions
Cti Biopharma 's Revenue in the fiscal year 2018 $ 26.29 millions
CTIC Revenue first quarter 2023 Y/Y Growth Comment
Cti Biopharma Corp achieved in the first quarter 2023, above Company average Revenue surge of 948.52% year on year, to $ 24.12 millions.
Looking into first quarter 2023 results within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Revenue growth. While Cti Biopharma Corp ' s Revenue doubling of 948.52% ranks overall at the positon no. 98 in the first quarter 2023.
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023
Cti Biopharma 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
8983.98 %
604.96 %
-100 %
(Dec 31 2013)
CTIC's I. Quarter Q/Q Revenue Comment
Cti Biopharma Corp achieved in the I. Quarter 2023 below company average Revenue rise of 14.4% quarter on quarter, to $ 24.12 millions.
I. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Cti Biopharma 's Revenue growth quarter on quarter, overall rank is 763.
Cti Biopharma Corp achieved in the I. Quarter 2023 below company average Revenue rise of 14.4% quarter on quarter, to $ 24.12 millions.
I. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Cti Biopharma 's Revenue growth quarter on quarter, overall rank is 763.
Cti Biopharma 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Sep 30 2022)
12 Months Ending (Jun 30 2022)
12 Months Ending (Mar 31 2022)
Cumulative Revenue 12 Months Ending
$ 75.77
$ 53.95
$ 0.00
$ 0.00
$ 0.00
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
#
#
#
#
#
Seqeuential Revenue Change (TTM)
40.45 %
-
-
-
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 618
# 0
# 0
# 0
# 0
Cumulative Revenue growth Comment
Cti Biopharma saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 948.52% year on year, to $ 76 millions if the fiscal year would have ended in Mar 31 2023. Cti Biopharma 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2022. And, Cti Biopharma realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Dec 31 2022 rise was beneth at 40.45 % from $53.95 millions achieved in the period from Dec 31 2022 to Mar 31 2022. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -0.4%.
Cti Biopharma Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Cti Biopharma saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 948.52% year on year, to $ 76 millions if the fiscal year would have ended in Mar 31 2023. Cti Biopharma 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2022. And, Cti Biopharma realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Dec 31 2022 rise was beneth at 40.45 % from $53.95 millions achieved in the period from Dec 31 2022 to Mar 31 2022. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -0.4%. The momentum is even more impressive from twelve months ended Dec 31 2022 exhibited at 40.45 % increase from $53.95 millions in the period from Dec 31 2022 to Mar 31 2022.
Cti Biopharma Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Cti Biopharma Revenue Growth Rates (CTIC), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1,430.99%